Lupin logo

LUPIN - Lupin Share Price

₹1036 -9.2  -0.9%

Last Trade - 13/04/21

Large Cap
Market Cap £4.54bn
Enterprise Value £4.74bn
Revenue £1.47bn
Position in Universe 83rd / 3106
Unlock LUPIN Revenue
Relative Strength (%)
1m +1.53%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.69%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
127,700 142,555 174,943 158,042 146,646 153,748 153,979 175,381 +3.8%
+27.8 -6.4 +13.9 -63.6 -21.7 -87.7 +1,106 +57.0
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, LupinLimited revenues decreased 1% to RS113.8B. Net incomebefore extraordinary items totaled RS7.56B vs. loss ofRS7.89B. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Net Income reflects Other Expenses decrease of4% to RS33.02B (expense), Finance Cost decrease of 57% toRS1.09B (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for LUPIN
Graphical History


LUPIN Revenue Unlock LUPIN Revenue

Net Income

LUPIN Net Income Unlock LUPIN Revenue

Normalised EPS

LUPIN Normalised EPS Unlock LUPIN Revenue

PE Ratio Range

LUPIN PE Ratio Range Unlock LUPIN Revenue

Dividend Yield Range

LUPIN Dividend Yield Range Unlock LUPIN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
LUPIN EPS Forecasts Unlock LUPIN Revenue
Profile Summary

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated March 1, 1983
Public Since November 30, 1994
No. of Shareholders: 299,792
No. of Employees: 18,302
Sector Healthcare
Industry Pharmaceuticals
Index S&P BSE 100 ,
Exchange National Stock Exchange of India
Shares in Issue 453,680,133
Free Float (0.0%)
Eligible for
LUPIN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LUPIN
Upcoming Events for LUPIN
Monday 24th May, 2021 Estimate
Full Year 2021 Lupin Ltd Earnings Release
Wednesday 4th August, 2021 Estimate
Q1 2022 Lupin Ltd Earnings Release
Thursday 12th August, 2021 Estimate
Lupin Ltd Annual Shareholders Meeting
Frequently Asked Questions for Lupin
What is the Lupin share price?

As of 13/04/21, shares in Lupin are trading at ₹1036, giving the company a market capitalisation of £4.54bn. This share price information is delayed by 15 minutes.

How has the Lupin share price performed this year?

Shares in Lupin are currently trading at ₹1036 and the price has moved by 25.42% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lupin price has moved by -22.57% over the past year.

What are the analyst and broker recommendations for Lupin?

Of the analysts with advisory recommendations for Lupin, there are there are currently 10 "buy" , 10 "hold" and 5 "sell" recommendations. The overall consensus recommendation for Lupin is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Lupin next release its financial results?

Lupin is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Lupin dividend yield?

The Lupin dividend yield is 0.58% based on the trailing twelve month period.

Does Lupin pay a dividend?

Last year, Lupin paid a total dividend of 6, and it currently has a trailing dividend yield of 0.58%. Looking ahead, Lupin has not announced an ex-dividend date yet.

When does Lupin next pay dividends?

Lupin has yet to annouce their ex-dividend date. The historic dividend yield on Lupin shares is currently 0.58%.

How do I buy Lupin shares?

To buy shares in Lupin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lupin?

Shares in Lupin are currently trading at ₹1036, giving the company a market capitalisation of £4.54bn.

Where are Lupin shares listed? Where are Lupin shares listed?

Here are the trading details for Lupin:

Country of listing: India
Exchange: NSI
Ticker Symbol: LUPIN
What kind of share is Lupin?

Based on an overall assessment of its quality, value and momentum, Lupin is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lupin share price forecast 2021?

Shares in Lupin are currently priced at ₹1036. At that level they are trading at 1.87% discount to the analyst consensus target price of 0.00.

Analysts covering Lupin currently have a consensus Earnings Per Share (EPS) forecast of 23.879 for the next financial year.

How can I tell whether the Lupin share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lupin. Over the past six months, the relative strength of its shares against the market has been -16.95%. At the current price of ₹1036, shares in Lupin are trading at 5.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lupin PE Ratio?

The Lupin PE ratio based on its reported earnings over the past 12 months is 43.57. The shares are currently trading at ₹1036.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Lupin?

Lupin's management team is headed by:

Kamal Sharma - NVC
Vinita Gupta - CEO
Naresh Gupta - CEX
Ramesh Swaminathan - CFO
Debabrata Chakravorty - CEX
Rajender Kamboj - CEX
Cyrus Karkaria - CEX
Manju Gupta - CHM
Rajendra Chunodkar - CEX
Jean-Luc Belingard - NID
Fabrice Egros - CEX
Yashwant Mahadik - CEX
Christine Mundkur - NID
Rob Funsten - IND
Mark McDade - IND
Who are the major shareholders of Lupin?

Here are the top five shareholders of Lupin based on the size of their shareholding:

Lupin Investments Pvt. Ltd. Corporation
Percentage owned: 45.32% (205.6m shares)
Life Insurance Corporation of India Insurance Company
Percentage owned: 5.16% (23.4m shares)
HDFC Asset Management Co., Ltd. Investment Advisor
Percentage owned: 4.15% (18.8m shares)
HDFC Balanced Advantage Fund Mutual Fund
Percentage owned: 1.7% (7.73m shares)
Jhunjhunwala (Rakesh Radheshyam) Individual Investor
Percentage owned: 1.6% (7.25m shares)
Similar to LUPIN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.